Press Release-April 27, 2015
ISMC, E-P Therapeutics, Forever Identity and ClinImmune/Caricord collaborate on studies and testing of UCB stem cell survivability under microgravity (Micro-G) simulation.
In May 2015, International Space Medicine Consortium (ISMC) will commence a study comparing the differentiation of umbilical cord blood (UCB) stem cell survivability under 1G and Micro-G conditions at its Micro-G laboratory in Connecticut. Micro-G simulates the conditions aboard the International Space Station (ISS) and activities in Low Earth Orbit (LEO). The UCB stem cells to be used for the study will be furnished by the ClinImmune/Caricord bank at the University of Colorado.
The study will also apply the E-peptide developed by E-P Therapeutics under 1G and Micro-G conditions and compare the functionality of the neural differentiated stem cells to measure the E- peptide action performance yield. The E-peptide, a small protein, has been observed to cause primary neural cells to develop dendrites. This suggests enhanced maturation will occur with the addition of E-peptide to UCB stem cells that are being stimulated for neural expression. The ClinImmune/Caricord team will also participate in the verification analysis post differentiation for neural therapeutic applications in 1G and Micro-G conditions.
As a part of these space medicine activities, ISMC has negotiated an exclusive partnership with Forever Identity to develop a 3-D holographic persona and is researching its application in interactive robotics and cognitive intelligence. Forever has researched and developed an application specific empathy platform that ISMC is actively investigating for robotic clinical psychology and diagnostic space medicine protocols.